Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Non Operating Income: 2015-2024

Historic Non Operating Income for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to -$14.1 million.

  • Seres Therapeutics' Non Operating Income rose 236.26% to $30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.7 million, marking a year-over-year increase of 741.89%. This contributed to the annual value of -$14.1 million for FY2024, which is 384.01% down from last year.
  • Per Seres Therapeutics' latest filing, its Non Operating Income stood at -$14.1 million for FY2024, which was down 384.01% from $5.0 million recorded in FY2023.
  • In the past 5 years, Seres Therapeutics' Non Operating Income ranged from a high of $5.0 million in FY2023 and a low of -$14.1 million during FY2024.
  • Moreover, its 3-year median value for Non Operating Income was -$3.7 million (2022), whereas its average is -$4.3 million.
  • As far as peak fluctuations go, Seres Therapeutics' Non Operating Income skyrocketed by 235.45% in 2023, and later plummeted by 384.01% in 2024.
  • Over the past 5 years, Seres Therapeutics' Non Operating Income (Yearly) stood at -$997,000 in 2020, then dropped by 8.83% to -$1.1 million in 2021, then tumbled by 237.97% to -$3.7 million in 2022, then soared by 235.45% to $5.0 million in 2023, then plummeted by 384.01% to -$14.1 million in 2024.